David’s career has been one of broad experience in hospital and primary health care, commencing with Intensive Care and Critical Care nursing in his youth until 26 years of age and the last 28 years marked by a unique and very successful management career in the pharmaceutical industry with medical, marketing, commercial and senior leadership depth in the pharmaceuticals and biotechnology industries. His background qualifications are in Nursing Science (he was a practicing Clinical Nurse Specialist in ICU for 6 years) with post graduate qualifications in marketing and business management developed during his pharmaceutical career..
Prior to joining Alexion in July 2008, to lead the introduction of unique biological products for ultra-rare and life threatening diseases in Asia Pacific, David was Vice President, Asia Pacific and Australian Managing Director of the Swiss biopharmaceutical company, Actelion from 2001 - 2008. From 1990 – 2001 David worked in a variety of medical, marketing, and business unit management roles in Australia and Globally for Roche in their Swiss HQ as a Global Business and Lifecycle Leader from 1997 - 2001.
For the past 17 years, David’s professional passion has been driven by branching out into the unique area of life threatening rare disease and he has focused working with companies with clear breakthrough drugs for such seriously life threatening indications. This passion is driven by his deep belief that no person inflicted with a serious rare disease should be penalized by the fact the disease is not a common and hence not so attractive to the large investments required to achieve development of therapy and solutions to save lives. He was able to further pursue his deep interest in making a difference for sufferers of life threatening ultra - rare disease by joining Alexion Inc when Soliris was recognized worldwide in 2008 with a Prix Gallien Award (US and France) as the world’s greatest breakthrough in biological medicine that year. Alexion has now grown to the point that it is clearly a world leader in both developing and launching new breakthrough therapies for ultra-rare disease..
David has also worked on Australian government working groups and committees such as the Pharmaceutical Education Council (2005 – 2008) and Chaired the Medicines Australia Biotechnology Working Group (MABIG) in 2006. This work enabled David to contribute to the development of reimbursement policies for biotechnology and rare disease sector within Australia.
In addition to David’s work in the pharmaceutical industry, he has also diversified in the past into leadership training and coaching with the well-recognized leadership thought leader, author and media commentator, Avril Henry, including contributing to her best-selling book in 2008 – “Tomorrows Leaders Today – Breaking Down Generational Barriers at Work”.
Try to solve the new Formula Cube! It works exactly like a Rubik's Cube but it is only $2, from China. Learn to solve it with the tutorial on rubiksplace.com or use the solver to calculate the solution in a few steps.